Mikhail Blagosklonny is a man of ample intellect and expertise. He is a professor, scientist, and expert. Mr. Blagosklonny’s educational background is rather impressive and extensive. Mikhail BLAGOSKLONNY holds both a M.D. and a PhD. He has an M.D. in internal medicine and a PhD in experimental medicine and cardiology. He has utilized knowledge from both degrees in his work as a scientist. Mikhail’s alma mater is First Pavlov State Medical University of St. Petersburg. Mr. Mikhail has applied his educational knowledge to a few roles as associate professor and professor. His professional background includes a role as associate professor at New York Medical College. He later became senior scientist at Ordway Research Institute, and following his role as senior scientist he became professor of oncology at Roswell Park Cancer Center. During his professional involvements he has also conducted extensive research on the topics of cancer therapy and anti-aging. He has over 270 research articles in peer-reviewed journals. Visit ResearchGate to keep up to date with Mikhail’s latest work.
In addition to his role as educator and scientist Mikhail Blagosklonny provides editorial services. His editorial achievements include his role as editor-in-chief of Aging, Cell Cycle, and Oncotarget. He has served a role as associate editor of Cancer Biology and Therapy, and he is a member of the editorial board of Cell Death and Differentiation. Mr. Mikhail is a productive man with extreme scholarly involvement. Although every editorial role is valuable Mr. Mikhail is perhaps most known for OncoTarget. Oncotarget is a multidisciplinary peer-reviewed journal. It provided free access and produces multiple articles a week. Founders desire to make information easily accessible.
Mikhail Blagosklonny researches topics that many individuals of society have interest in today. This includes the topic of anti-aging. Anti-aging has been an area of much interest, funding, and research. One need not question why. Finality and death is one of the few issue of humanity society is yet to remedy. However, Mr. Mikhail is searching anti-aging methods. In his article ” Rejuvenating immunity: ” anti-aging drug today” eight years later”, he discussed past research, progress, and concerns. In this article Mr. Blagosklonnny discusses previous criticisms of a TOR- centric model and the results found from the model. TOR, also known as Target of Rapamycin, uses rapamycin to treat aging and prevent disease. If used consistently with the proper dosage it can extend the healthy life-span of a human. Although the TOR- centric model can help extend the overall life-span it cannot completely eliminate death. Unknown disease is likely to come along at some point leading to fatality. These are amazing and exciting findings! Mikhail Blagosklonny has proven to produce informational, productive, and insightful research. Through the marriage of his knowledge about aging and oncology Mikhail works to find a way to eliminate the process of aging related to cancer.
Mikhail Blagoskonnny is using his knowledge to make a positive difference in the world, and his research may one day change humanity as we know it. Mr. Blagoskanny attributes his drive and interest to a desire for a healthy and disease free community.